Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
752
datasets available to search
ShareScore release 0.9.0
Dataset results
752 results for “Osteoporosis”
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
ClinicalTrials.gov study NCT01377467. IPD Sharing: NO. Countries: 1. Publications: 2.
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
ClinicalTrials.gov study NCT00051558. IPD Sharing: Not stated. Countries: 6. Publications: 3.
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
ClinicalTrials.gov study NCT00680953. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
ClinicalTrials.gov study NCT04064411. IPD Sharing: NO. Countries: 5. Publications: 1.
Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
ClinicalTrials.gov study NCT05345691. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
ClinicalTrials.gov study NCT03164928. IPD Sharing: YES. Countries: 13. Publications: 0.
Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis
ClinicalTrials.gov study NCT00745121. IPD Sharing: Not stated. Countries: 3. Publications: 4.
Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
ClinicalTrials.gov study NCT00010439. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Brief Osteoporosis Education to Increase Awareness in Middle Aged and Elderly.
ClinicalTrials.gov study NCT05936177. IPD Sharing: YES. Countries: 1. Publications: 6.
GAS5 protects against osteoporosis by targeting UPF1/SMAD7 axis in osteoblast differentiation
Open the record for dataset details and reuse information.
Liquiritigenin reduces osteoclast activity in zebrafish model of glucocorticoid-induced osteoporosis
<p>Drug and therapies currently used to treat human bone diseases have a lot of severe side effects. Liquiritigenin is a flavonoid extracted from Glycyrrhiza glabra roots which has been reported to have positive effects in vitro on osteoblasts activity and bone mineralization as well as inhibitory effect on osteoclasts differentiation and activity in vitro. The present study was aimed to evaluate the in vivo effects of liquiritigenin on bone structure and metabolism in physiological and pathological conditions using Danio rerio as experimental animal model. Treatments with liquiritigenin were performed on embryos to evaluate the osteogenesis during skeletal development. Other treatments were performed on adult fish affected by glucocorticoid-induced osteoporosis to assay the therapeutic potential of liquiritigenin in the reversion of bone-loss phenotype in scale model. Liquiritigenin treatment of zebrafish embryo significantly enhances the osteogenesis during development in a dose-dependent manner. In addition, liquiritigenin inhibits the formation of the osteoporotic phenotype in adult zebrafish model of glucocorticoid-induced osteoporosis preventing osteoclast activation in scales. Interestingly, liquiritigenin does not counteract the loss of osteoblastic activity in scales. The liquiritigenin exhibits in vivo anti-osteoporotic activity on adult fish scale model. It can be considered a good candidate to develop new drugs against osteoporosis.</p>
Age-dependent modulation of bone metabolism in zebrafish scales as new model of male osteoporosis in lower vertebrates
<p>After middle age, in human bone, the resorption usually exceeds formation resulting in bone loss and increased risk of fractures in the aged population. Only few in vivo models in higher vertebrates are available for pathogenic and therapeutic studies about bone aging. Among these, male Danio rerio (zebrafish) can be successfully used as low vertebrate model to study degenerative alterations that affect the skeleton during aging, reducing the role of sex hormones.In this paper, we investigated the early bone aging mechanisms in male zebrafish (3, 6, 9 months old) scales evaluating the physiological changes and the effects of prednisolone, a pro-osteoporotic drug.The results evidentiated an age-dependent reduction of the mineralization rate in the fish scales, as highlighted by growing circle measurements. Indeed, the osteoblastic ALP activity at the matrix deposition site was found progressively downregulated.The higher TRAP activity was found in 63% of 9-month-old fish scales associated with resorption lacunae along the scale border. Gene expression analysis evidentiated that an increase of the tnfrsf1b (homolog of human rank) in aging scales may be responsible for resorption stimulation.Interestingly, prednisolone inhibited the physiological growth of the scale and induced in aged scales a more significant bone resorption compared with untreated fish (3.8% vs 1.02%). Bone markers analysis shown a significant reduction of ALP/TRAP ratio due to a prednisolone-dependent stimulation of tnfsf11 (homolog of human rankl) in scales of older fish.The results evidentiated for the first time the presence of a senile male osteoporosis in lower vertebrate. This new model could be helpful to identify the early mechanisms of bone aging and new therapeutic strategies to prevent age-related bone alterations in humans.</p>
Prediction of femoral osteoporosis using machine-learning analysis with radiomics features and abdomen-pelvic CT: A retrospective single center preliminary study
<p>Dataset of prediction of osteoporosis using APCT, radiomics and machine learning analysis.</p>
Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and bone markers in patients with severe fractured osteoporosis: a real-life study
<p><strong>Abstract</strong></p> <p>Purpose: Osteoporosis is characterized by a loss of bone mass, increased bone fragility and susceptibility to fracture. Sequential treatment with bisphosphonates or denosumab (Dmab) after teriparatide (TPT) discontinuation may represent a valid treatment option, but the optimal sequential treatment strategy is unknown.</p> <p>Methods: This retrospective study enrolled 56 osteopenic/osteoporotic patients with fragility fractures who received 24 months of treatment with TPT followed by 24 months of treatment with zoledronic acid (ZOL) (TPT+ZOL) or Dmab (TPT+Dmab). Clinical features, incident fractures, bone mineral density (BMD) measurements, and bone marker profiles were characterized. Ordinary one-way ANOVA adjusted for multiple testing analyzed the difference between median T-scores at baseline, after 24 months of TPT, and after 2 doses of ZOL or at least 3 doses of Dmab when variables failed the normality test.</p> <p>Results: Twenty-three patients received TPT+ZOL (19 females, 4 males; median [IR] age, 74.3 [66.9, 78.6] years) and 33 patients received TPT+Dmab (31 females, 2 males; mean±SD age, 66.6±11.3 years). Mean lumbar and hip T-scores were significantly higher after sequential treatment with both TPT+ZOL and TPT+Dmab (all p<0.05 vs baseline). In particular, the mean lumbar T-score increased in about 80% of patients by 8.5±58% after ZOL, while after Dmab, the mean lumbar T-score was -9.6±36%. Mean±SD femur neck and hip T-scores increased by 12±13% and 9±31%, respectively, after treatment with ZOL, while the change in femur neck and hip T-scores after Dmab were 5±41% and 27±36%, respectively, No significant between-group differences were identified. Fragility fractures occurred in 3 (13%) patients treated with TPT+ZOL and in 5 (15%) patients treated with TPT+Dmab.</p> <p>Conclusion: Sequential therapy with TPT+ZOL increased bone mineralization at the lumbar level and stabilized bone mineralization at the femoral level. Both ZOL and Dmab are effective sequential treatments after TPT.</p>
A Machine Learning based approach to osteoporosis classification: correlational and comparative analysis between Osseus and DXA exams
<p>The osseus dataset is composed of data from 505 individuals who underwent the osseus triage and DXA exam at the University Hospital Onofre Lopes of Federal University of Rio Grande do Norte, Brazil. This dataset provides elementary data to analyze the prediction of changes in bone mineral density by Osseus using supervised classification algorithms. Supplementary file presents the dictionary used during the data analysis.</p>
Peripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures
ClinicalTrials.gov study NCT06551155. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
ClinicalTrials.gov study NCT00191425. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of Parathyroid Hormone in Men With Osteoporosis
ClinicalTrials.gov study NCT00000427. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Rare Variation and Remote Gene Regulation of Osteoporosis Related Phenotypes in Han Chinesse
ClinicalTrials.gov study NCT04129671. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
The Effect of Yoga Asana 'Vrksasana (Tree Pose)' on Balance in the Patients With Osteoporosis
ClinicalTrials.gov study NCT03882853. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.